COST PER CLINICAL OUTCOMES WITH VEDOLIZUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN BRAZIL
Tassia Decimoni 1
Gabriela Muricy 1
Haridarshan Patel 2
Dirk Demuth 3
1 Takeda Pharmaceuticals International. Inc., São Paulo, Brazil
2 Immensity Consulting, Inc, Chicago, United States of America
3 Takeda Development Centre Europe Ltd, Global Outcomes Research, London, United Kingdom
Conference
UEG Week 2016
Citation
United European Gastroenterology Journal; 2016: 2 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at office@ueg.eu
Social Sharing